New hope for aspirin-sensitive asthma and polyp sufferers: dupilumab study reveals how it works
NCT ID NCT05575037
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 20 times
Summary
This study looks at how the drug dupilumab helps people with aspirin-exacerbated respiratory disease (AERD), a condition that includes asthma, nasal polyps, and reactions to aspirin. Seventeen adults with AERD and impaired smell will receive dupilumab for 8 weeks. Researchers will measure nasal fluid markers and smell tests to understand the drug's effects and how it reduces symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASAL POLYPS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.